We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Biomarkers Panel Used for Pleural and Peritoneal Effusions Diagnosis

By LabMedica International staff writers
Posted on 25 Sep 2019
The quantification of biomarkers in cavity fluids may aid in the etiological diagnosis and in patients' management. More...
Laboratory investigation of cavity effusions involves the evaluation of biochemical, immunological, microbiological, molecular and cellular parameters.

The broad spectrum of etiologic causes of pleural effusion (PE) and peritoneal effusion (PerE) justifies studies with biomarkers quantified in samples obtained through thoracentesis and/or paracentesis, procedures considered minimally invasive and at a low risk for patients.

Scientists at the University of Sao Paulo (San Paulo, Brazil) evaluated Samples of pleural or peritoneal fluid from 120 patients submitted to thoracentesis or paracentesis for diagnostic investigation. Each sample was representative of one patient. The team evaluated the following biomarkers: carcinoembryonic antigen (CEA), vascular endothelial growth factor A (VEGF-A) programmed death-ligand 1 (PD-L1/B7-H1), neutrophil gelatinase-associated lipocalin (NGAL), triggering receptor expressed in myeloid cells type-1(TREM-1), and gamma-interferon (IFNγ).

Samples of PE or PerE were prepared for analysis in a 96-well plate utilizing a custom Luminex Human Magnetic Assay. CEA, VEGF-A, PD-L1, NGAL, TREM-1 and IFNγ were quantified using a MAGPIX analytical test instrument. The concentrations of Calprotectin were obtained by a ‘sandwich’ ELISA test with CALP human kit and analyzed on Victor X3 plate reader in a 450 nm low-pass absorbance. The assay used for adenosine desaminase (ADA) was the Quimiada Adenosina Deaminase kit, and a concentration above 30 U/L is presumptive of tuberculosis.

The team reported that for malignant effusion (ME) diagnosis, CEA and NGAL presented superior performance than VEGF-A, PD-L1 and CALP. A CEA-NGAL association showed good sensitivity (86.6%) and accuracy (79.2%). For non-tuberculous infectious effusion (NTBIE), NGAL presented the best performance with sensitivity (75.0%), specificity (62.0%) and accuracy (65.0%) higher than TREM-1 and CALP; however, when associated, although with good sensitivity, there was important decrease in specificity. For tuberculous pleural effusion (TPE), IFNγ-ADA presented excellent sensitivity (100%), specificity (87.6%), NPV (100%) and accuracies (~90%).

The authors concluded that a hybrid panel composed by the biomarkers CEA, NGAL, IFNγ and ADA seems to be useful in discriminating between ME and TPE etiology, both lymphocytic effusions. For non-tuberculous infectious effusion, the panel used did not demonstrate diagnostic advantages over the classic literature parameters. The study was published in the October 2019 issue of the journal Clinica Chimica Acta.

Related Links:
University of Sao Paulo


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.